Understanding the world of genetics
It doesn’t have to be complicated. It can be as simple as based on a DNA sample to evaluate if you could by exposed you to a chance to develop certain diseases like cancer, or to find out how your current or future pharmaceutical treatments may work on you, or if newly diagnosed early breast cancer treatment may not require chemotherapy, or which targeted therapies will work based on tumor unique genetic profile. We are here to help you explore which genetic tests may be right for you and what those tests could show you about your health.
EndoPredict® is a multi-gene test for breast cancer patients.
Using a specially developed procedure, EndoPredict provides physicians with information to devise personalized treatment plans for their newly diagnosed early breast cancer patients.
The EndoPredict test is based on the analysis of tumor prolipherative and hormone receptor-related genes in combination with the classical prognostic factors of nodal status and tumour size delivering an unique highly reliable prognostic score on the risk of breast cancer’s early and distant recurrence for a time interval as long as 15 years.
EndoPredict’s EPclin prognostic score will influence whether or not chemotherapy is necessary be prescribed together with endocrine therapy for the management of your early breast cancer.
Presently more than 30,000 women worldwide had their treatment plan decisions shaped by EndoPredict EPClin score results.
Other tests that may fit your health interests:
Pharmacogenomics test that predicts how patients will respond to drug therapy based on their individual genetic make-up.
Confronted with the pitfalls of the current therapy or facing the challenge of starting a pharmaceutical treatment, we realize that each of us is different. PGxOne Plus is offering an unique comprehensive insight on each individual’s relevant genetic patterns influencing the way drugs work in their body.
LiquidGx™ is a non-invasive cancer test, based on a simple blood sample, for selecting relevant solid tumor targeted therapies and it represents an alternative to tissue-based biopsies, for when tumor tissue can be difficult to sample.
Patients and doctors become partners in the journey to faster, smarter and more efficient personalized medical solutions.
Prolaris® is a genomic test developed to aid healthcare professionals in predicting prostate cancer aggressiveness in conjunction with clinical parameters such as Gleason score and PSA, in order to better define the treatment and monitoring strategy for their patients.